Form 4: Insider Sells Sagimet Stock for Tax Obligations

Sagimet Biosciences Chief Legal & Admin. Officer Elizabeth Rozek sold 2,622 shares of Series A Common Stock to cover tax withholding obligations.

Summary

• Elizabeth Rozek, Chief Legal & Admin. Officer of Sagimet Biosciences Inc., reported a transaction involving the sale of company stock.
• She sold 2,622 shares of Series A Common Stock on February 10, 2026.
• The shares were sold at a price of $5.3602 per share.
• The sale was automatic and non-discretionary, executed specifically to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Rozek beneficially owns 190,959 shares of Series A Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as the sale was non-discretionary and for tax purposes, which is a common and expected part of executive compensation, rather than a signal of a lack of confidence in the company's future.

Positives

• The sale was explicitly stated as non-discretionary and for tax withholding purposes, which is a common and often neutral event for insider transactions related to compensation.

Negatives

• An insider sale, even for tax purposes, results in a reduction of the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales for tax withholding are a routine occurrence, especially with restricted stock unit vesting, and typically do not signal a change in management's long-term view of the company's prospects unless they are part of a larger, discretionary selling pattern.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the non-discretionary nature mitigates concerns about management confidence.

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale for tax purposes related to RSU vesting, which does not indicate a change in the company's fundamentals or management's outlook. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Sagimet Biosciences, SGMT, Elizabeth Rozek, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units